Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Fujian Shengdi Pharmaceutical obtained the approval of China's drug administrator to start clinical trials for HRS9531 injection to treat chronic kidney disease.
HRS9531 is a novel dual agonist that activates both GIP and GLP-1 receptors, which helps regulate metabolism and improve insulin sensitivity, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 3% higher Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments